Clinical Performance of the Cobalt-Chromium Biodegradable Polymer Coated Sirolimus-Eluting Stent in an Unselected Real-World Population

Prakash Chandwani, Atul D. Abhyankar, Jayesh S. Prajapati, Sanjay C. Porwal, Ashok S. Thakkar

Apollo Hospitals International Limited, Gandhinagar, India.
Heart and General Hospital, Jaipur, India.
KLEs Dr. PrabhakarKore Hospital & Medical Research Centre, Belgaum, India.
Sahajanand Medical Tech. Pvt. Ltd., Surat, India.
Shree B.D. Mehta Mahavir Heart Institute, Surat, India.

DOI: 10.4236/ijcm.2014.55034                

Abstract

OBJECTIVE: The primary objective of the S-CORE registry was to assess the safety and efficacy of the Supralimus-Core? sirolimus-eluting stent deployment for the treatment of coronary artery disease and event-free survival of patients treated with this coronary stent. METHODS: S-CORE Registry is an observational, single-arm, non-randomized, post-marketing surveillance multicenter registry in which 562 patients undergoing single or multi-vessel percutaneous coronary intervention were enrolled. The pre-specified primary outcome was the rate of major adverse cardiac events (MACE), defined as the composite of cardiac death, myocardial infarction (MI), target lesion revascularisation (TLR) and target vessel revascularisation (TVR) at 12-month post-procedure. Stent thrombosis (ST) served as the safety endpoint. RESULTS: A total of 640 lesions were treated in 562 enrolled patients (mean age 57.4 ± 10.7 years) with average stent length of 25.0 ± 9.0 mm. Stent delivery was successful in 99% cases. A total of 554 (98.6%) patients have been followed up to 12 months. The incidence of MACE at 30 days and 6 months was 7 (1.2%) and 12 (2.1%) respectively. The composite rate of MACE at a 12-month clinical follow-up was 19 (3.4%), consisting of 12 (2.1%) cardiac deaths, 0 (0%) MI, 6 (1.1%) TLR and 1 (0.2%) TVR. The long-term follow-up of this registry is going on to confirm safety and efficacy profiles. CONCLUSIONS: This multicenter registry demonstrated satisfactory safety and efficacy profiles, as evidenced by low rates of major adverse cardiac events up to 12 months, for the cobalt-chromium biodegradable polymer-based sirolimus-eluting Supralimus-Core? stent in a “real-world” setting.

Keywords

Coronary Artery Disease; Biodegradable Polymer; Sirolimus-Eluting Stent

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Morice, M.C., Serruys, P.W., Sousa, J.E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., Molnar, F. and Falotico, R. (2002) A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. New England Journal of Medicine, 346, 1773-1780. http://dx.doi.org/10.1056/NEJMoa012843
[2]	Stone, G.W., Ellis, S.G., Cox, D.A., Hermiller, J., O’Shaughnessy, C., Mann, J.T., Turco, M., Caputo, R., Bergin, P. and Greenberg, J. (2004) A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. New England Journal of Medicine, 350, 221-231. http://dx.doi.org/10.1056/NEJMoa032441
[3]	Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O’Shaughnessy, C., Caputo, R.P., Kereiakes, D.J., Williams, D.O. and Teirstein, P.S. (2003) Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. New England Journal of Medicine, 349, 1315-1323. http://dx.doi.org/10.1056/NEJMoa035071
[4]	Feres, F., Costa, J.R. and Abizaid, A. (2006) Very Late Thrombosis after Drug-Eluting Stents. Catheterization and Cardiovascular Interventions, 68, 83-88. http://dx.doi.org/10.1002/ccd.20692
[5]	Pfisterer, M., Brunner-La Rocca, H.P., Buser, P.T., Rickenbacher, P., Hunziker, P., Mueller, C., Jeger, R., Bader, F., Osswald, S. and Kaiser, C. (2006) Late Clinical Events after Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting versus Bare-Metal Stents. Journal of the American College of Cardiology, 48, 2584-2591. http://dx.doi.org/10.1016/j.jacc.2006.10.026
[6]	Daemen, J., Wenaweser, P., Tsuchida, K., Abrecht, L., Vaina, S., Morger, C., Kukreja, N., Jüni, P., Sianos, G. and Hellige, G. (2007) Early and Late Coronary Stent Thrombosis of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Routine Clinical Practice: Data from a Large Two-Institutional Cohort Study. The Lancet, 369, 667-678. http://dx.doi.org/10.1016/S0140-6736(07)60314-6
[7]	Kounis, N.G., Giannopoulos, S., Tsigkas, G.G. and Goudevenos, J. (2012) Eosinophilic Responses to Stent Implantation and the Risk of Kounis Hypersensitivity Associated Coronary Syndrome. International Journal of Cardiology, 156, 125-132. http://dx.doi.org/10.1016/j.ijcard.2011.05.052
[8]	Nakazawa, G., Ladich, E., Finn, A.V. and Virmani, R. (2008) Pathophysiology of Vascular Healing and Stent Mediated Arterial Injury. EuroIntervention: Journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 4, C7-C10.
[9]	Patel, M.R. and Holmes Jr, D.R. (2008) Next-Generation Drug-Eluting Stents. JAMA: The Journal of the American Medical Association, 299, 1952-1953. http://dx.doi.org/10.1001/jama.299.16.1952
[10]	Lange, R.A., Hillis, L.D., Stone, G., Moses, J., Ellis, S., Trikalinos, T., Alsheikh-Ali, A., Tatsioni, A., Nallamothu, B. and Kent, D. (2010) Second-Generation Drug-Eluting Coronary Stents. New England Journal of Medicine, 362, 1728. http://dx.doi.org/10.1056/NEJMe1001069
[11]	Alfonso, F. and Fernandez, C. (2011) Second-Generation Drug-Eluting Stents Moving the Field Forward. Journal of the American College of Cardiology, 58, 26-29. http://dx.doi.org/10.1016/j.jacc.2011.03.013
[12]	Kereiakes, D.J., Cox, D.A., Hermiller, J.B., Midei, M.G., Bachinsky, W.B., Nukta, E.D., Leon, M.B., Fink, S., Marin, L. and Lansky, A.J. (2003) Usefulness of a Cobalt Chromium Coronary Stent Alloy. The American Journal of Cardiology, 92, 463-466. http://dx.doi.org/10.1016/S0002-9149(03)00669-6
[13]	Hagemeister, J., Baer, F.M., Schwinger, R.H. and Hopp, H.W. (2005) Compliance of a Cobalt Chromium Coronary Stent Alloy—The COVIS Trial. Current Controlled Trials in Cardiovascular Medicine, 6, 17. http://dx.doi.org/10.1186/1468-6708-6-17
[14]	Legrand, V., Kelbaek, H., Hauptmann, K.E., Glogar, D., Rutsch, W., Grollier, G., Vermeersch, P., Elias, J. and De Cock, C.C. (2006) Clinical and Angiographic Analysis with a Cobalt Alloy Coronary Stent (Driver) in Stable and Unstable Angina Pectoris. The American Journal of Cardiology, 97, 349-352. http://dx.doi.org/10.1016/j.amjcard.2005.08.051
[15]	Burzotta, F., Trani, C., Todaro, D., Mazzari, M.A., Porto, I., De Vita, M., Brugaletta, S., Coroleu, S.F., Niccoli, G. and Leone, A.M. (2009) Outcome of Patients Treated by a Novel Thin-Strut Cobalt-Chromium Stent in the Drug-Eluting Stent Era: Results of the SKICE (Skylor in Real World Practice) Registry. Catheterization and Cardiovascular Interventions, 73, 457-465. http://dx.doi.org/10.1002/ccd.21882
[16]	Seth, A., Chandra, P., Chouhan, N.S. and Thakkar, A.S. (2012) A First-In-Man Study of Sirolimus-Eluting, Biodegradable Polymer Coated Cobalt Chromium Stent in Real Life Patients. Indian Heart Journal, 64, 547-552. http://dx.doi.org/10.1016/j.ihj.2012.07.011
[17]	Cutlip, D.E., Windecker, S., Mehran, R., Boam, A., Cohen, D.J., van Es, G.-A., Steg, P.G., Morel, M.-A., Mauri, L. and Vranckx, P. (2007) Clinical End Points in Coronary Stent Trials a Case for Standardized Definitions. Circulation, 115, 2344-2351. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.685313
[18]	Weisz, G., Leon, M.B., Holmes, D.R., Kereiakes, D.J., Popma, J.J., Teirstein, P.S., Cohen, S.A., Wang, H., Cutlip, D.E. and Moses, J.W. (2009) Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. Journal of the American College of Cardiology, 53, 1488-1497. http://dx.doi.org/10.1016/j.jacc.2009.01.050
[19]	Finn, V., Kolodgie, F.D., Harnek, J., Guerrero, L., Acampado, E., Tefera, K., Skorija, K., Weber, D.K., Gold, H.K. and Virmani, R. (2005) Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimusor Paclitaxel-Eluting Stents. Circulation, 112, 270-278. http://dx.doi.org/10.1161/CIRCULATIONAHA.104.508937
[20]	Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T., Mihalcsik, L., Tespili, M., Valsecchi, O. and Kolodgie, F.D. (2004) Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Elut-ing Stent Should We Be Cautious? Circulation, 109, 701-705. http://dx.doi.org/10.1161/01.CIR.0000116202.41966.D4
[21]	Garg, S. and Serruys, P. (2009) Biodegradable Stents and Non-Biodegradable Stents. Minerva Cardioangiologica, 57, 537.
[22]	O’Neill, W.W., Dixon, S.R. and Grines, C.L. (2005) The Year in Interventional Cardiology. Journal of the American College of Cardiology, 45, 1117-1134. http://dx.doi.org/10.1016/j.jacc.2005.01.006
[23]	Navarese, E.P., Kubica, J., Castriota, F., Gibson, C.M., De Luca, G., Buffon, A., Bolognese, L., Margheri, M., Andreotti, F. and Di Mario, C. (2011) Safety and Efficacy of Biodegradable vs. Durable Polymer Drug-Eluting Stents: Evidence from a Meta-Analysis of Randomised Trials. EuroIntervention, 7, 985-994. http://dx.doi.org/10.4244/EIJV7I8A155
[24]	Garg, S. and Serruys, P.W. (2010) Coronary Stents: Looking Forward. Journal of the American College of Cardiology, 56, S43-S78. http://dx.doi.org/10.1016/j.jacc.2010.06.008
[25]	Briguori, C., Sarais, C., Pagnotta, P., Liistro, F., Montorfano, M., Chieffo, A., Sgura, F., Corvaja, N., Albiero, R. and Stankovic, G. (2002) In-Stent Restenosis in Small Coronary Arteries Impact of Strut Thickness. Journal of the American College of Cardiology, 40, 403-409. http://dx.doi.org/10.1016/S0735-1097(02)01989-7
[26]	Kastrati, A., Mehilli, J., Dirschinger, J., Dotzer, F., Schühlen, H., Neumann, F.-J., Fleckenstein, M., Pfafferott, C., Seyfarth, M. and Schömig, A. (2001) Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial. Circulation, 103, 2816-2821. http://dx.doi.org/10.1161/01.CIR.103.23.2816
[27]	Pache, J., Kastrati, A., Mehilli, J., Schühlen, H., Dotzer, F., Hausleiter, J., Fleckenstein, M., Neumann, F.-J., Sattelberger, U. and Schmitt, C. (2003) Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO-2) Trial. Journal of the American College of Cardiology, 41, 1283-1288. http://dx.doi.org/10.1016/S0735-1097(03)00119-0
[28]	Abhyankar, A. and Thakkar, A.S. (2012) In Vivo Assessment of Stent Recoil of Biodegradable Polymer-Coated Cobalt-Chromium Sirolimus-Eluting Coronary Stent System. Indian Heart Journal, 64, 541-546. http://dx.doi.org/10.1016/j.ihj.2012.07.005
[29]	Abhyankar, A., Prajapati, J. and Reddy, S. (2013) Early Vascular Healing with Biodegradable Polymer Coated Sirolimus-Eluting Coronary Stent Implantation: Assessed by Optical Coherence Tomography Results at 4-Month Follow-Up. Minerva Cardioangiologica, 61, 313-322.